Catalent (NYSE:CTLT) Price Target Lowered to $58.00 at Barclays

Catalent (NYSE:CTLT – Get Rating) had its price target cut by Barclays from $62.00 to $58.00 in a report published on Tuesday, The Fly reports. They currently have an overweight rating on the stock.

A number of other equities research analysts have also weighed in on CTLT. Robert W. Baird reduced their price objective on Catalent from $123.00 to $75.00 in a research report on Wednesday, November 2nd. Royal Bank of Canada reduced their price target on Catalent from $125.00 to $73.00 and set an outperform rating on the stock in a research report on Wednesday, November 2nd. TheStreet lowered Catalent from a b- rating to a c+ rating in a research report on Friday, October 28th. Argus lowered Catalent from a buy rating to a hold rating in a research report on Monday, November 7th. Finally, Bank of America lowered Catalent from a buy rating to a neutral rating and reduced their price target for the company from $125.00 to $60.00 in a research report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Catalent currently has a consensus rating of Hold and an average target price of $92.40.

Catalent Price Performance

Catalent stock opened at $49.57 on Tuesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.08 and a current ratio of 2.86. Catalent has a 52 week low of $40.69 and a 52 week high of $115.33. The stock has a market capitalization of $8.92 billion, a P/E ratio of 21.18, a price-to-earnings-growth ratio of 3.41 and a beta of 1.24. The stock has a fifty day moving average of $46.22 and a 200-day moving average of $72.04.

Catalent (NYSE:CTLT – Get Rating) last posted its quarterly earnings results on Tuesday, November 1st. The company reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.24). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a return on equity of 12.55% and a net margin of 8.83%. On average, sell-side analysts expect that Catalent will post 2.93 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Manja Boerman sold 780 shares of the business’s stock in a transaction dated Monday, December 5th. The stock was sold at an average price of $51.70, for a total value of $40,326.00. Following the transaction, the insider now directly owns 15,860 shares of the company’s stock, valued at approximately $819,962. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Michael J. Grippo sold 2,451 shares of the company’s stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the transaction, the senior vice president now directly owns 17,792 shares of the company’s stock, valued at approximately $1,171,247.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Manja Boerman sold 780 shares of the company’s stock in a transaction that occurred on Monday, December 5th. The stock was sold at an average price of $51.70, for a total value of $40,326.00. Following the transaction, the insider now directly owns 15,860 shares in the company, valued at $819,962. The disclosure for this sale can be found here. 0.58% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its stake in Catalent by 9.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 22,303,561 shares of the company’s stock worth $2,392,949,000 after buying an additional 2,011,520 shares during the period. Vanguard Group Inc. raised its stake in shares of Catalent by 0.9% in the third quarter. Vanguard Group Inc. now owns 19,223,242 shares of the company’s stock worth $1,390,994,000 after purchasing an additional 178,443 shares during the last quarter. BlackRock Inc. raised its stake in shares of Catalent by 5.2% in the third quarter. BlackRock Inc. now owns 16,086,469 shares of the company’s stock worth $1,164,016,000 after purchasing an additional 792,923 shares during the last quarter. State Street Corp raised its stake in shares of Catalent by 0.9% in the third quarter. State Street Corp now owns 7,126,800 shares of the company’s stock worth $515,695,000 after purchasing an additional 67,054 shares during the last quarter. Finally, Veritas Asset Management LLP raised its stake in shares of Catalent by 1.0% in the third quarter. Veritas Asset Management LLP now owns 6,957,775 shares of the company’s stock worth $503,465,000 after purchasing an additional 65,734 shares during the last quarter. 99.38% of the stock is owned by institutional investors and hedge funds.

Catalent Company Profile

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.